Sangamo Therapeutics, Inc., a leading genomic medicine company, has reported promising updated data from the Phase 1/2 STAAR study. This study explores the efficacy of isaralgagene civaparvovec (ST-920) as a treatment for Fabry disease. The analysis, which reflects data up to September 12, 2024,
Clinical trials are fundamental to the development of new medical treatments and the advancement of healthcare. However, enrolling and retaining participants in these trials has been a persistent challenge over the years. The perceived difficulty of involvement, alongside high dropout rates, can
The 21st century has seen the pharmaceutical industry face mounting challenges such as escalating competition and pricing pressures. Consequently, developers and manufacturers are pioneering innovative strategies to differentiate their products and instill value, particularly in the saturated
Pharmaceutical manufacturers are tasked with the critical responsibility of monitoring and reporting safety events to ensure patient safety and regulatory compliance. This process involves detecting, documenting, evaluating, reporting, and following up on adverse events, product quality complaints,
The latest study from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center provides compelling evidence that CAR T cell therapy does not induce secondary cancers. This finding comes from an extensive analysis of data involving over 700
Polymetastatic cancer, a condition where cancer has spread to more than 10 spots throughout the body, often leaves patients with limited treatment options. Recent advancements in cancer therapy have focused on high-precision radiation treatments to combat this extensive metastasis. Researchers from
